Eli Lilly’s research division has generated considerable fervor for its first-line reading of Phase II of its next generation of Alzheimer’s drugs, donanemab. But after releasing the data this weekend, you can expect some of the experts in the field to take a much more measured approach to the chances of regulatory approval.
Lilly announced a statistically significant result for the new primary endpoint: change from baseline to the 76-week score on the integrated Alzheimer’s Disease Assessment Scale, or iADRS, which is a combined score of cognition and function that indicated that the beta drug amyloid N3pG could slow the decline of early-stage patients, which has been eagerly consumed in an area of R&D with millions of patients who currently have nothing to deal with memory-destroying disease.
Requires premium subscription
Unlock this article along with other benefits by signing up for one of our paid plans.